Evogene Ltd.

2.82-0.1000-3.42%Vol 248.21K1Y Perf -9.22%
Sep 24th, 2021 16:00 DELAYED
BID2.78 ASK2.87
Open2.86 Previous Close2.92
Pre-Market- After-Market2.81
 - -  -0.01 -0.35%
Target Price
12.50 
Analyst Rating
— 0.00
Potential %
343.26 
Finscreener Ranking
 —    -
Insiders Trans % 3/6/12 mo.
-/-/- 
Value Ranking
★★★★ —    55.48
Insiders Value % 3/6/12 mo.
-/-/- 
Growth Ranking
★★★     53.27
Insiders Shares Cnt. % 3/6/12 mo.
-/-/- 
Income Ranking
 —    -
Price Range Ratio 52W %
5.60 
Earnings Rating
Buy
Market Cap72.62M 
Earnings Date
17th Nov 2021
Alpha-0.01 Standard Deviation0.22
Beta1.26 

Today's Price Range

2.782.90

52W Range

2.3810.24

5 Year PE Ratio Range

-7.40-3.20

Summary:

Sell

Technical Indicators: Sell
Moving Averages: Strong Sell
Performance
1 Week
-7.24%
1 Month
0.71%
3 Months
-21.67%
6 Months
-38.96%
1 Year
-9.22%
3 Years
-9.03%
5 Years
-56.75%
10 Years
-

TickerPriceChg.Chg.%
EVGN2.82-0.1000-3.42
AAPL146.920.09000.06
GOOG2 852.6616.13000.57
MSFT299.35-0.2100-0.07
XOM57.590.51000.89
WFC47.920.12000.25
JNJ164.36-0.5000-0.30
FB352.967.00002.02
GE103.800.84000.82
JPM163.041.86001.15
Financial StrengthValueIndustryS&P 500US Markets
12.70
12.70
0.02
0.04
-48.20
Leverage Ratio 1.40
ProfitabilityValueIndustryS&P 500US Markets
27.80
-2 430.30
-2 211.80
-1 431.30
-
RevenueValueIndustryS&P 500US Markets
1.14M
0.03
-22.23
-
Earnings HistoryEstimateReportedSurprise %
Q02 2021--0.15-
Q01 2021--0.17-
Q04 2020--0.25-
Q03 2020--0.17-
Q02 2020--0.16-
Q01 2020--0.24-
Q04 2019--0.24-
Q03 2019--0.16-
Earnings Per EndEstimateRevision %Trend
3/2018 QR-0.190.00-
6/2018 QR-0.190.00-
12/2021 FY-0.707.89Positive
12/2022 FY-0.728.86Positive
Next Report Date17th Nov 2021
Estimated EPS Next Report-
Estimates Count-
EPS Growth Next 5 Years %-
Volume Overview
Volume248.21K
Shares Outstanding25.75M
Shares Float34.50M
Trades Count1.50K
Dollar Volume11.29M
Avg. Volume867.50K
Avg. Weekly Volume250.95K
Avg. Monthly Volume467.35K
Avg. Quarterly Volume366.38K

Evogene Ltd. (NASDAQ: EVGN) stock closed at 2.82 per share at the end of the most recent trading day (a -3.42% change compared to the prior day closing price) with a volume of 248.47K shares and market capitalization of 72.62M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 139 people. Evogene Ltd. CEO is Ofer Haviv.

The one-year performance of Evogene Ltd. stock is -9.22%, while year-to-date (YTD) performance is -40%. EVGN stock has a five-year performance of -56.75%. Its 52-week range is between 2.38 and 10.24, which gives EVGN stock a 52-week price range ratio of 5.60%

Evogene Ltd. currently has a PE ratio of -4.10, a price-to-book (PB) ratio of 1.86, a price-to-sale (PS) ratio of 102.00, a price to cashflow ratio of 81.70, a PEG ratio of 2.32, a ROA of -33.84%, a ROC of -45.87% and a ROE of -47.47%. The company’s profit margin is -%, its EBITDA margin is -2 211.80%, and its revenue ttm is $1.14 Million , which makes it $0.03 revenue per share.

Of the last four earnings reports from Evogene Ltd., there were 0 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $0.00 for the next earnings report. Evogene Ltd.’s next earnings report date is 17th Nov 2021.

The consensus rating of Wall Street analysts for Evogene Ltd. is (0), with a target price of $12.5, which is +343.26% compared to the current price. The earnings rating for Evogene Ltd. stock is Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Evogene Ltd. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Evogene Ltd. has a Sell technical analysis rating based on Technical Indicators (ADX : 28.07, ATR14 : 0.20, CCI20 : -60.74, Chaikin Money Flow : -0.10, MACD : -0.01, Money Flow Index : 37.19, ROC : -5.69, RSI : 46.64, STOCH (14,3) : 13.04, STOCH RSI : 0.00, UO : 50.87, Williams %R : -86.96), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Evogene Ltd. in the last 12-months were:

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
0
0
0 (0.00 %)
Moderate Buy
0
0
0 (0.00 %)
Hold
0
0
1 (100.00 %)
Moderate Sell
0
0
0 (0.00 %)
Strong Sell
0
0
0 (0.00 %)
Summary Rating--Hold
3.00

Evogene Ltd.

Evogene Ltd is a computational biology company targeting to revolutionize product development for life-science based industries, including human health, agriculture, and industrial applications. The company established its technology, the Computational Predictive Biology (CPB) platform. The CPB platform is designed to computationally discover and develop life-science products based on microbes, small molecules and genetic elements as the core components for such products. It holds a number of subsidiaries utilizing the CPB platform, for the development of human microbiome-based therapeutics, medical cannabis, ag-biologicals, ag-chemicals, seed traits and ag-solutions for castor oil production.

CEO: Ofer Haviv

Telephone: +972 89311900

Address: 13 Gad Feinstein Street, Rehovot 7612002, , IL

Number of employees: 139

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

100%0%

Bearish Bullish

52%48%

Bearish Bullish

67%33%

News

Stocktwits